Jazz Pharmaceuticals (JAZZ) PT Raised to $337 at UBS on GEA Approval for Ziihera
Tweet Send to a Friend
(Updated - September 11, 2026 9:06 AM EDT)
UBS analyst Ashwani Verma raised the price target on Jazz Pharmaceuticals ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
UBS analyst Ashwani Verma raised the price target on Jazz Pharmaceuticals ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
